US 6,586,394 B1 · Tissue-derived tumor growth inhibitor

Abstract

This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequence Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Clu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-β3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.

Claims1

Dependent claims

A homogeneous polypeptide composition having a molecular weight of 25(26) kDa as determined by SDS-PAGE and having the property of inhibiting growth of a mink lung cell line, CCL64 (ATCC Accession Number PTA-3450) wherein said composition is prepared by a process comprising:

(a) obtaining an acidified ethanol extract of human umbilical cord;
(b) hydrophobic interaction chromatography of said extract;
(c) reverse phase high pressure liquid chromatography on a C18 column using an acetonitrile gradient;
(d) rechromatography by reverse phase high pressure liquid chromatography on a CN column using a 2-propanol gradient;
(e) recovery of fractions from step (d) having the property of inhibiting growth of a mink lung cell line, CCL64 (ATCC Accession Number PTA-3450);
and
(f) subjecting the fractions so recovered to SDS-PAGE.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

08/188,197Filed 27 Jan 1994 · continuation in part

Priority

19 Apr 1985

Granted

1 Jul 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/52
From animals; from humans: cytokines; Lymphokines; Interferons
A61K 35/44
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61K 35/50
Reproductive organs: placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
C07K 14/495
Growth factors; Growth regulators: transforming growth factor [TGF]

Family

Application06/725,003Parent of this continuation-in-part · filed 19 Apr 1985

Application06/847,931Parent of this continuation-in-part · filed 7 Apr 1986

Application06/922,121Parent of this continuation-in-part · filed 20 Oct 1986

Application07/111,022Parent of this continuation · filed 20 Oct 1987

Application07/768,100Parent of this continuation · filed 30 Sep 1991

Application08/147,904Parent of this continuation-in-part · filed 4 Nov 1993

Application08/147,904Parent of this continuation

Application07/111,022Parent of this continuation-in-part

US 6,586,394 B1This patent

From the US filing history. Foreign family members aren’t listed.

Tissue-derived tumor growth inhibitor

Life of this patent

Tissue-derived tumor growth inhibitor

Life of this patent

Abstract

Claims1